Business Wire

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho

Del

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months).

“Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest that trifluridine/tipiracil, in combination with bevacizumab, can improve progression-free survival in advanced disease, offering a new option to metastatic colorectal cancer patients. These results are an important first step and will need to be investigated further in a global Phase III study.”

Servier has announced the results of a large interim analysis of the Phase IIIb early access study PRECONNECT which is assessing trifluridine/tipiracil in 462 patients with mCRC who have been previously treated with standard therapy. The study showed median progression-free survival of 2.8 months, consistent to that seen in the Phase III RECOURSE trial, which was used as the basis for the European Commission approval of trifluridine/tipiracil in 2016. A similar disease control rate (36.8%) and time to ECOG deterioration (8.7 months) compared to RECOURSE were also shown.

“The incidence of colorectal cancers is growing globally and for those diagnosed with metastatic disease the five-year survival is just 11%,” said Ali Zeaiter, Head of Servier Oncology clinical development department. “For patients with metastatic disease not candidates for intensive therapy or for those who have been pre-treated with chemotherapy and targeted therapies, there are limited options that can extend their survival. We are committed to improving outcomes for people living with cancer, and both TASCO-1 and PRECONNECT studies demonstrate the potential of LONSURF® to provide a substantial benefit to patients with metastatic colorectal cancer.”

ENDS

About TASCO-1

TASCO-1 is an international, randomized, non-comparative Phase II trial designed to evaluate efficacy of trifluridine/tipiracil in combination with bevacizumab and the current standard of care (capecitabine and bevacizumab) for patients with untreated metastatic colorectal cancer, who are not suitable for intensive therapy.

In addition to the primary endpoint of PFS, secondary endpoints of the trial included overall survival and disease control rate. The combination of trifluridine/tipiracil and bevacizumab was manageable, with the most frequently observed toxicities being gastrointestinal and hematologic. There was a 3.9% serious febrile neutropenia event rate reported in both arms of the trial.

Servier and Taiho Pharmaceutical are committed to exploring all possible combinations of LONSURF® in the treatment of metastatic colorectal cancer, with a number of ongoing clinical trials.

About PRECONNECT

PRECONNECT is an ongoing international, multicentre, Phase IIIb study designed to further assess safety and efficacy of trifluridine/tipiracil in daily practice by giving eligible adult metastatic colorectal cancer patients access to trifluridine/tipiracil. The study aims to treat 1,000 patients in 20 countries; as of 29th May 2018 the study had recruited 794 patients across 14 countries.

The PRECONNECT trial gives early access to trifluridine/tipiracil for adult patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. PRECONNECT will also assess the quality of life of patients; preliminary data are anticipated in 2019.

About colorectal cancer

Colorectal cancer is the third most common cancer worldwide with approximately 1.4 million new diagnoses in 2012.1 Each year there are over 690,000 deaths making it the fourth biggest cancer killer worldwide (after lung, liver and gastric cancer).2 Those with metastatic disease (where the cancer has spread from the primary site) the average five-year survival is approximately 11%.3 Standard chemotherapy regimens for advanced metastatic colorectal cancer include fluoropyrimidines, oxaliplatin, irinotecan or targeted treatments, such as those that target vascular endothelial growth factors (VEGF) or endothelial growth factor receptors (EGFR).

About LONSURF ® (trifluridine/tipiracil)

LONSURF® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF® is registered in Japan, USA, European Union and in many other countries. In the European Union, LONSURF® is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.4

LONSURF® is recommended by the National Institute for Health and Care Excellence (NICE),5 NCCN6,7 and ESMO Guidelines8 for the treatment of adult patients with metastatic colorectal cancer.

In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSURF®.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Find us on Social Media:

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.

For more information visit: https://www.taiho.co.jp/en/

1 World Health Organisation. Globocan (2012), colorectal cancer. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=colorectal Last accessed June 2018

2 Cancer Research UK. Worldwide cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#heading-One Last accessed June 2018

3 American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html Last accessed June 2018

4 European Medicines Agency. EPAR Lonsurf. Available from: http://www.ema.europa.eu/ema/. Last accessed June 2018.

5 NICE TA405. Available at: www.nice.org.uk/guidance/TA405.

6 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

7 National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.

8 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.

Contact information

Press:
Servier
Sonia MARQUES
media@servier.com
Tél. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
or
Karine BOUSSEAU
media@servier.com
Tél. +33 (0)1 55 72 60 37

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event14.11.2018 21:00Pressemelding

MapleStory, the iconic global MMORPG from Nexon America, is bringing the first phase of its long-awaited battle with the sinister villain, the Black Mage. Between November 14 through November 28, players can take part in the “Gathering of Heroes” event to join the Maple Alliance and prepare their armies to soon combat the Black Mage. The Black Mage has long been the main antagonist behind MapleStory. His story originated with the role of bringing balance to Maple World, but turned dark as he realized the only way to save Maple World was to destroy it. Now that his seal has been broken, players will need to work together to defeat the legendary boss. The Gathering of Heroes event adds the Maple Alliance outpost, where players can hone their skills and prepare to level up in preparation of for their battle against the Black Mage, as well as adds various leveling updates. The main goal of the Alliance is to gather “Determination” and power up the holy light in the outpost to be able to fi

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 20:07Pressemelding

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he

Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels14.11.2018 16:55Pressemelding

The Fondation IPSEN is delighted to invite you to a theatre performance about familial upheavals when a family member is affected by Alzheimer’s disease or cerebral dementia (November 21 st at 4pm). This play has been written by playwright Brian Daniels and directed by Jeni Draper, has had more than 200 performances and explores with insight and humour the impact of early onset dementia on family life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005695/en/ (Graphic: Business Wire) Free entrance, but registration is mandatory (limited seats): Please click here NOVEMBER 21 st , 4 pm “Le Petit Théâtre de la Fondation IPSEN” 65 quai George Gorse 92150 Boulogne-Billancourt (Metro Line 9, Pont-de-Sèvres) About the Project Our “Science for People” program is composed of accessible meetings and webinars to improve access to science. Brian Daniels’ play “Don’t leave me now” is about caregivers of people with Alzheimer’s Dise

HCL Technologies Celebrates 10 Years of Success in the Nordics14.11.2018 16:44Pressemelding

HCL Technologies (HCL), a leading global technology company, is celebrating its 10-year anniversary in the Nordic region. During this time, the company has achieved significant successes, which have seen the Nordics grow to become HCL’s largest market in Europe. Today, HCL employs more than 1,600 people in the Nordics representing 31 nationalities, with 55 large-scale transformational clients including four out of the six Fortune Global 500 companies in the region. While several significant milestones have been successfully achieved, HCL looks forward to the future and is dedicated to helping its clients in the Nordics to drive innovation and growth. The celebration coincides with a series of initiatives to mark this occasion starting with the opening of a new office at HCL’s Nordics headquarters in Central Stockholm. “We are humbled by the success that we have achieved together with our clients, colleagues and partners in the Nordics,” said Pankaj Tagra, EVP Nordic and DACH Head, HCL

The Next Industrial Transformation is Here: Rockwell Automation is Helping Businesses Prepare to Succeed at Automation Fair 201814.11.2018 16:35Pressemelding

Today, at its annual Automation Fair, Rockwell Automation unveiled its new brand promise: Expanding Human Possibility by combining the imaginations of people with the intelligence of machines. The brand promise supports the company’s emphasis on bringing The Connected Enterprise to life and how, by linking people, machines and data across an entire business, manufacturers become more effective and productive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005671/en/ Blake Moret, chairman and CEO, Rockwell Automation, shares his vision for bringing the Connected Enterprise to life and how manufacturers can expand human possibility by linking people, machines and data across their businesses, helping them to become more effective and productive. (Photo: Business Wire) “The new Rockwell Automation brand emphasizes the central role that people play in advanced manufacturing and underscores our focus on ways we maximize per

Hospital in Cox’s Bazar Will Offer 24/7 Medical Aid to 140,000 Rohingya Refugees14.11.2018 15:53Pressemelding

A 100-bed capacity hospital opened in Cox’s Bazar district in Bangladesh. It is expected to serve 140,000 Rohingya refugees based in the Kutupalong camp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005631/en/ Sheikh Sultan bin Ahmed Al Qasimi, humanitarian envoy of the foundation and chairman of SMC inaugurated the hospital last Friday. (Photo: Business Wire) This round-the-clock medical facility, built and managed by Médecins Sans Frontières (MSF) – Doctors without Borders with the support of Sharjah-based international humanitarian organisation, The Big Heart Foundation (TBHF), aims to treat 7,200 people in its first year. Part of TBHF’s leading humanitarian efforts to reach out globally to vulnerable communities, this hospital project was supported by AED 3 million donation from Sharjah Media Corporation (SMC), through its public fundraising initiative on healthcare projects, and will offer much-needed relief to